Maternal exposure to busulfan reduces the cell number in the somatosensory cortex associated with delayed somatic and reflex maturation in neonatal rats

Gouveia, Henrique José Cavalcanti Bezerra; Manhães-de-Castro, Raul; Santana, Bárbara Juacy Rodrigues Costa de; Mendonça, Carolina Rodrigues; Albuquerque, Glayciele Leandro de; Visco, Diego Bulcão; Lacerda, Diego Cabral; Toscano, Ana Elisa

doi:10.1016/j.jchemneu.2019.101710

Cited by 9 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the neonatal period (P7, P14 and P21) and at the target ages (P28 and P36) body weight was measured using a digital scale (Marte®, model S‐1000, 0.1 g). During the same periods, body length was examined using a digital caliper (Jomarca® 0.01 mm) to measure the distance from the anterior tip of the nasal bone to the base of the tail (Gouveia et al, 2019; Santana Muniz et al, 2014). Measurements were taken between 9 and 11 AM.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Neonatal kaempferol exposure attenuates gait and strength deficits and prevents altered muscle phenotype in a rat model of cerebral palsy

Visco

Castro

Silva

et al. 2022

Intl J of Devlp Neuroscience

Self Cite

View full text Add to dashboard Cite

Cerebral palsy (CP) is characterized by brain damage at a critical period of development of the central nervous system, and, as a result, motor, behavioural and learning deficits are observed in those affected. Flavonoids such as kaempferol have demonstrated potential anti-inflammatory and neuroprotective properties for neurological disorders. This study aimed to assess the effects of neonatal treatment with kaempferol on the body development, grip strength, gait performance and morphological and biochemical phenotype of skeletal muscle in rats subjected to a model of CP. The groups were formed by randomly allocating male Wistar rats after birth to four groups as follows: C = control treated with vehicle, K = control treated with kaempferol, CP = CP treated with vehicle and CPK = CP treated with kaempferol. The model of CP involved perinatal anoxia and sensorimotor restriction of the hind paws during infancy, from the second to the 28th day of postnatal life. Treatment with kaempferol (1 mg/kg) was performed intraperitoneally during the neonatal period. Body weight and length, muscle strength, gait kinetics and Abbreviations: CP, cerebral palsy; LH, left hind paw; PA, perinatal anoxia; p-AKT, phospho-protein kinase B/AKT; p-S6, phospho-ribosomal protein S6; P, postnatal day; RH, right hind paw.

show abstract

Section: Methodsmentioning

confidence: 99%

“…During the same periods, body length was examined using a digital caliper (Jomarca ® 0.01 mm) to measure the distance from the anterior tip of the nasal bone to the base of the tail (Gouveia et al, 2019;Santana Muniz et al, 2014). Measurements were taken between 9 and 11 AM.…”

Section: Analysis Of Body Measurementsmentioning

confidence: 99%

Neonatal kaempferol exposure attenuates gait and strength deficits and prevents altered muscle phenotype in a rat model of cerebral palsy

Visco

Castro

Silva

et al. 2022

Intl J of Devlp Neuroscience

Self Cite

View full text Add to dashboard Cite

show abstract

“…The antimetabolites cytarabine and fluorouracil can be applied during the 2nd and 3rd trimester, but methotrexate should be avoided during the entire pregnancy, due to multiple birth defects [ 2 ]. The alkylating agents cyclophosphamide and dacarbazine were evaluated to be safe [ 2 ], while busulfan showed negative effects in the development of the central nervous system in animal models [ 37 ]. The anthracyclines doxorubicin and epirubicin are considered to be safe during the 2nd and 3rd trimester, nevertheless, idarubicin and daunorubicin should be avoided [ 2 ].…”

Section: Therapeutic Principles In Women With Cancer In Pregnancymentioning

confidence: 99%

Cancer and Pregnancy: A Comprehensive Review

Schwab

Anić

Hasenburg

2021

Cancers

View full text Add to dashboard Cite

Cancer diagnosis and treatment in pregnant women is a challenging situation. A multidisciplinary network of specialists is required to guide both, the expecting mother and the unborn child through the diagnostic workup and the cytotoxic therapy, by balancing the respective risks and benefits. Tumor entity, stage, biology and gestational week at diagnosis determine the appropriate approach. As premature delivery emerged as one of the main risk factors for adverse long-term outcome of the progeny, it should be avoided, if reasonable from the oncological perspective. This article offers a comprehensive review with respect to the various aspects of cancer in pregnancy.

show abstract